BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 1981076)

  • 1. Selective alpha 1 inhibition with doxazosin in hypertensive smokers and non-smokers: haemodynamic and metabolic effects.
    Westheim A; Daae LN; Kierulf P; Brusletto B; Holme I; Syvertsen JO
    J Hypertens Suppl; 1990 Sep; 8(5):S41-6. PubMed ID: 1981076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effect of doxazosin on blood pressure, lipids, fibrinogen and plasminogen activator inhibitor. A comparative study among smokers and non-smokers with essential hypertension].
    Daae LN; Kierulf P; Brusletto B; Westheim A; Holme I; Syvertsen JO
    Tidsskr Nor Laegeforen; 1991 Apr; 111(9):1102-5. PubMed ID: 1827216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of doxazosin and atenolol on serum lipids and blood pressure in hypertensive smokers.
    Talseth T; Westlie L; Daae LN
    J Hypertens Suppl; 1990 Sep; 8(5):S47-51. PubMed ID: 1981077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute effects of doxazosin and atenolol on smoking-induced peripheral vasoconstriction in hypertensive habitual smokers.
    Lecerof H; Bornmyr S; Lilja B; De Pedis G; Hulthén UL
    J Hypertens Suppl; 1990 Sep; 8(5):S29-33. PubMed ID: 1981074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha 1-adrenoreceptor blockade and the molecular basis of lipid metabolism alterations.
    Pool JL; Lenz ML; Taylor AA
    J Hum Hypertens; 1990 Oct; 4 Suppl 3():23-33. PubMed ID: 1979819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxazosin: a new alpha 1-adrenergic antagonist.
    Babamoto KS; Hirokawa WT
    Clin Pharm; 1992 May; 11(5):415-27. PubMed ID: 1349855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A long-term study of atenolol and doxazosin in mild and moderate hypertension.
    Talseth T; Westlie L; Daae L
    J Hum Hypertens; 1990 Oct; 4 Suppl 3():39-44. PubMed ID: 2148194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative effects of doxazosin and enalapril in patients with arterial hypertension and exercise-induced acute myocardial ischemia].
    Passarelli P; Galiè N; Limonetti P; Branzi A; Magnani B
    Cardiologia; 1991 Oct; 36(10):777-83. PubMed ID: 1686851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension--results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects.
    Feher MD; Henderson AD; Wadsworth J; Poulter C; Gelding S; Richmond W; Sever PS; Elkeles RS
    J Hum Hypertens; 1990 Oct; 4(5):571-7. PubMed ID: 1980930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxazosin in hypertension: results of a general practice study in 4809 patients.
    Langdon CG; Packard RS
    Br J Clin Pract; 1994; 48(6):293-8. PubMed ID: 7848789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined effect of doxazosin and pindolol on blood pressure control and lipid concentrations in patients with essential hypertension selected from general practice. Hunter Hypertension Research Group.
    J Hum Hypertens; 1992 Jun; 6(3):181-4. PubMed ID: 1352827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood pressure and heart rate response to repeated smoking before and after beta-blockade and selective alpha 1 inhibition.
    Groppelli A; Omboni S; Parati G; Mancia G
    J Hypertens Suppl; 1990 Sep; 8(5):S35-40. PubMed ID: 1981075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Doxazosin in the treatment of light-to-moderate arterial hypertension in a non-comparative multicenter study].
    Pessina AC
    Clin Ter; 1995 Jan; 146(1):3-12. PubMed ID: 7705011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
    Ohta Y; Tsuchihashi T; Onaka U; Eto K; Ueno M
    Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-related effects of doxazosin on plasma lipids and aortic fatty streak formation in the hypercholesterolemic hamster model.
    Foxall TL; Shwaery GT; Stucchi AF; Nicolosi RJ; Wong SS
    Am J Pathol; 1992 Jun; 140(6):1357-63. PubMed ID: 1351367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effects of doxazosin and atenolol on blood pressure and blood lipids: a one-year, double-blind study in 228 hypertensive patients.
    Talseth T; Westlie L; Daae L; Vatle S
    Am Heart J; 1988 Dec; 116(6 Pt 2):1790-6. PubMed ID: 2904752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Reducing blood pressure and modification of coronary risk factors by therapy with doxazosin].
    Hitzenberger G; Ganzinger U
    Wien Klin Wochenschr; 1993; 105(13):371-6. PubMed ID: 8351927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with doxazosin in general medical practice.
    Rosenthal J
    Am Heart J; 1988 Dec; 116(6 Pt 2):1748-57. PubMed ID: 2904745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.